AMENDMENT #2 Compound Pharmaceuticals for Dept of Pharmacy, Carl R. Darnall Army Medical Center, Fort Hood, Tx.

Amendment / Modification

This amendment serves to post Questions and Answers related to the solicitation.

• Prescription Process for Compounded Drugs: The government clarified that compounded pharmaceuticals under this contract are designated for Inpatient Pharmacy settings and/or emergency departments as critical items (crash carts). Unlike outpatient pharmacy, these do not require individual patient prescriptions. Instead, medication orders and authorizations from providers are used, and these are billed as inpatient medical expenses.
• Standard Practice: The use of compound pharmaceuticals for inpatient settings/emergency departments with provider orders is a common practice among other Military Treatment Facilities (MTFs). The CRDAMC has been utilizing compound pharmaceuticals for inpatient care and critical emergency response for some time.

This amendment addresses questions regarding the prescription process for compounded drugs, as detailed in the "Description of Amendment/Modification" section.

No changes to proposal deadlines, requirements, or evaluation factors are indicated by this amendment. It solely provides clarification on a specific operational aspect.

Amendment / Modification

This amendment (0001) to Solicitation W81K0026QA064, dated 29 JAN 2026, makes the following key changes:

• FAR Clause 52.244-2, Subcontracts: This clause is added, establishing the Prime Contractor as the single point of responsibility for all contract performance, including the acts and omissions of subcontractors. It clarifies that a combination of capabilities between the Prime Contractor and a subcontractor to meet a single requirement is not permissible, and government approval of a subcontract does not relieve the Prime Contractor of responsibility.

• Addendum to 52.212-1 (Instructions to Offerors) and 52.212-2 (Evaluation):

  • Prime Contractor and Subcontractor Requirements: Reinforces the Prime Contractor's overall responsibility for performance, whether by their own forces or subcontractors. It mandates the submission of executed Teaming Agreements as part of the proposal package, clearly delineating roles and responsibilities. Failure to provide a signed Teaming Agreement for any proposed subcontractor may render the proposal non-responsive.
  • Offeror Requirements: Clarifies that offerors must be able to provide the entirety of the requested compound pharmaceuticals to be eligible for award. Partial quantities or partial listed items will not be technically acceptable.

• CLIN 0001 Modification: The language "Subject to Availability of Funds" has been removed from CLIN 0001.

• FAR Clause 52.244-2 (Subcontracts) has been added.

• Addendum to 52.212-1 and 52.212-2 have been modified to include specific requirements regarding subcontractor responsibility and the submission of Teaming Agreements, as well as the requirement for offerors to provide the entirety of the requested pharmaceuticals.

• CLIN 0001 has been modified.

• Offerors must now submit Teaming Agreements if proposing subcontractors for substantive work. Failure to do so may result in non-responsiveness.

• Offerors must confirm their ability to provide the entirety of the requested compound pharmaceuticals; otherwise, they are ineligible for award.

• The deadline for questions was 3 February 2026, and responses were to be published by 5 February 2026. The quote due date is specified in the portal.

Solicitation / RFP / RFQ

This solicitation, W81K0026QA064, is for the procurement of compound pharmaceuticals. The government is seeking offers for these products to meet specific requirements.

• The solicitation details specific compound pharmaceuticals, including Succinylcholine Chloride, Oxytocin, L.E.T. (Lidocaine, Epinephrine, Tetracaine), and Phenylephrine HCl.

• Quantities and specific formulations (e.g., concentration, volume, base solution) are provided for each item.

• Minimum shelf life requirements (e.g., 45 days at room temperature) and storage conditions are specified.

• Offerors must be able to provide the ENTIRETY of the requested compound pharmaceuticals; partial offers will be considered ineligible for award.

• Products must be compounded using only FDA-approved drugs, containers, and diluents.

• Compliance with Trade Agreements Act (TAA) is required for ingredients.

• Delivery must be within +/- 10% of USP standards.

• Compliance with the Compounding Quality Act Title I of the Drug Quality and Security Act of 2013 is required.

• Compliance with Current Good Manufacturing Practices (cGMP) (section 503b) is mandatory.

• Products must be labeled according to NPSG.03.04.01 for Joint Commission standards.

• QI/QA certification is required for every batch, regardless of size.

• 24/7 customer service is required.

• Compliance with DEA Licensing requirements for manufacturing and distribution of controlled substances is necessary.

• Specific elements of compliance for the Carl R. Darnall Army Medical Center (CRDAMC) are outlined, noting that patient-specific prescriptions do not meet bulk compound requirements.

• The period of performance spans multiple years, with specific delivery periods outlined for each item, generally from October 1st to September 30th of subsequent years, starting in 2026 and extending to 2030.

• Pricing arrangement is Firm Fixed Price.

• The solicitation issue date is January 29, 2026.

• The offer due date is February 12, 2026, at 10:00 AM local time.

• Award will be made using a Lowest Price Technically Acceptable (LPTA) source selection process.

• Quotes must be submitted electronically via email to sheryl.j.egans.civ@health.mil.

• Questions regarding the solicitation are due by February 3, 2026, 8 AM CST.

• Responses to questions will be published on SAM.gov by February 5, 2026.

• Quotes must be clear, concise, and include sufficient detail for effective evaluation.

• Offerors must provide documented proof of certification/accreditations (FDA or PCAB), USP Chapter compliance, and a Quality Control system.

• Technical acceptability is a mandatory requirement for award. Documentation must clearly meet minimum requirements.

• Pricing must be submitted for all compound pharmaceuticals, including unit and total extended prices.

• Offerors agree to hold prices for ninety (90) days from the quote submission.

• The acquisition is set aside for Small Business.

• NAICS Code: 325412, Size Standard: 1300.

• The document includes numerous FAR and DFARS clauses incorporated by reference and in full text, covering various aspects such as contract terms, representations and certifications, payment instructions, and evaluation criteria.